Peripheral T-cell lymphoma complicated by immunoglobulin A pemphigus: A case report and literature review

Chen, Lingjuan; Yang, Bohan; Fan, Jiquan; Yang, Kunyu; Liu, Hongli; Wu, Gang

doi:10.3892/ol.2014.2088

Cited by 5 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunoblotting or immunoprecipitation shows several proteins, such as desmoplakin, envoplakin, periplakin, bullous pemphigoid antigen 1, and alpha-2microglobulin 1. PNP is poorly responsive to corticosteroids and conventional treatments such as MTX [26]. Clinical picture, histopathologic exam, DIF result, and good response to treatment confirmed PV.…”

Section: Discussionmentioning

confidence: 86%

“…The patient had Hodgkin's lymphoma as a risk factor for PNP and IgA pemphigus; however, the clinical picture and the investigation ruled out these hypotheses [25,26]. IgA pemphigus is more associated with T cell lymphoma.…”

Section: Discussionmentioning

confidence: 90%

“…However, large population studies did not confirm this association [27]. Lymphoma could help in the autoimmune process, exposing autoantigens and promoting the ideal environment for immunological activation in the context of a highly antigenic viral disease [26]. Autoimmune phenomena can occur after mild covid conditions [9][10][11][12][13].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Pemphigus Vulgaris After COVID-19: a Case of Induced Autoimmunity

Medeiros

Neto

França

et al. 2021

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Bullae autoimmune diseases can be induced by environmental factors in a genetically susceptible individual, and viruses may be important triggers for this process. Coronavirus disease 2019 (COVID-19) is a multisystemic disease known for developing many types of skin lesions. However, little is known about post-COVID-19 manifestations. A previous healthy male patient, 43 years old, with resistant mediastinal Hodgkin's lymphoma stage II diagnosed in 2019, without treatment at the moment, developed monomorphic flaccid bullae on the trunk 40 days after testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although he had risk factors for IgA and paraneoplastic pemphigus, there were no elements for these diseases. The investigation confirmed a pemphigus vulgaris (PV). PV had a good response to treatment with prednisolone 1 mg/kg per day, and methotrexate 15 mg subcutaneously was added per week. The patient was discharged with oral methotrexate and prednisolone at the same dose. Prednisolone was decreased by 20 mg per day during the follow-up. Viruses such as herpesvirus, cytomegalovirus, and varicela zoster can act as triggers for PV. This process is not immediate after the infection because it depends on the change in antibodies initially produced against the virus that start to identify antigens present in the skin's anchoring structures. SARS-CoV-2 can induce autoimmunity, as seen in Guillán-Barré syndrome and in Kawasaki disease. It is a highly immunogenic virus that is the perfect agent for triggering PV. This case can be considered a cutaneous autoimmune post-COVID-19 manifestation.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Pemphigus Vulgaris After COVID-19: a Case of Induced Autoimmunity

Medeiros

Neto

França

et al. 2021

SN Compr. Clin. Med.

View full text Add to dashboard Cite

show abstract

“…1) [41]. Beyond these entities, other NDs such as neutrophilic panniculitis and immunoglobulin A (IgA) pemphigus [42][43][44] have been more rarely reported to arise in the context of HMs. Overlap/transitional forms between the different entities as well as extracutaneous localisations have also been reported in association with underlying HMs [45].…”

Section: Neutrophilic Dermatosesmentioning

confidence: 99%

Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review

et al. 2020

View full text Add to dashboard Cite

Haematological malignancies induce important alterations of the immune system, which account for the high frequency of autoimmune complications observed in patients. Cutaneous immune-mediated diseases associated with haematological malignancies encompass a heterogeneous group of dermatoses, including, among others, neutrophilic and eosinophilic dermatoses, autoantibody-mediated skin diseases, vasculitis and granulomatous dermatoses. Some of these diseases, such as paraneoplastic pemphigus, are associated with an increased risk of death; others, such as eosinophilic dermatoses of haematological malignancies, run a benign clinical course but portend a significant negative impairment on a patient's quality of life. In rare cases, the skin eruption reflects immunological alterations associated with an unfavourable prognosis of the associated haematological disorder. Therapeutic management of immune-mediated skin diseases in patients with haematological malignancies is often challenging. Systemic corticosteroids and immunosuppressive drugs are considered frontline therapies but may considerably augment the risk of serious infections. Indeed, developing a specific targeted therapeutic approach is of crucial importance for this particularly fragile patient population. This review provides an up-to-date overview on the immune-mediated skin diseases most frequently encountered by patients with onco-haematological disorders, discussing new pathogenic advances and therapeutic options on the horizon.

show abstract